Can IL-17F signalling be modulated by treatment with TNFi? In PsA pts non responders to previous TNFi, there was increased expression of IL17F-related gene signature. Suggesting a potential mechanism for the consistent level of clinical response observed with BKZ. Abstract https://t.co/D6fvp18UTz

• https://x.com/AdelaCastro222/status/1932816471576432744/photo/1
• https://x.com/AdelaCastro222/status/1932816471576432744/photo/1

In #InflammatoryArthritis, baseline depression was linked to ↑ presenteeism & ↓ QoL at baseline + 3mo, but not absenteeism. Data from 9-country study provide further evidence that mental health is key to supporting work outcomes in RA, PsA & axSpA. @RheumNow #EULAR2025 #OP0028

#EULAR2025 Abstr#OP0074 Manufacturing time for CAR-T can be a hindrance. Preliminary study (N=10 #SLE patients) of CD19/BCMA dual-targeting CAR-T developed on the novel FasTCAR-T platform with next-day manufacturing, showed promising efficacy and safety signals @RheumNow https://t.co/bgF04qe9C7

• https://x.com/Yuz6Yusof/status/1932816990076592491/photo/1

Worried about cancer risk with ts/bDMARDs in RA? Real-world data from over 4,600 patients says: don’t be. No increased risk of cancer (incl. NMSC) for JAKi, IL6i, CD20i, or CTLA4-A vs TNFi in long-term registry follow-up. Abstract#OP0065 @RheumNow #EULAR2025

Early intensive therapy in PsA. STAMP RCT in early PsA: •ACR50 at 3mo: 43% (early secukinumab) vs 22% (SoC) •MDA at 3mo: 48% vs 25% •PASI90 at 3mo: 60% vs 22% By 12months: outcomes similar, but early secukinumab led to faster control and fewer therapy escalations. https://t.co/TKa5z24NQX

• https://x.com/synovialjoints/status/1932818843367338030/photo/1

Can lowering serum urate also lower CV risk? In >116k patients w/ #gout, achieving SU <360 µmol/L in 12m ↓ 5yr MACE risk (HR 0.89, pooled Δsurvival +1.4%). Greater effect in >65s. Gout management = CV prevention? @RheumNow #EULAR2025 #OP0005 https://t.co/NRAerUBemN

• https://x.com/DrMiniDey/status/1932818858206740699/photo/1

STAMP RCT early SEC vs. SoC 120pts Retention 58% vs 30% ACR 20, 50, 70 and MDA: better outcome at Month 3 but no difference at Month 6 Dactylitis no difference Of note here SoC was a tight T2T strategy! @RheumNow #OP0092 #EULAR2025 https://t.co/8zHs5CRFV5

• https://x.com/AurelieRheumo/status/1932818904197255196/photo/1
• https://x.com/AurelieRheumo/status/1932818904197255196/photo/1
• https://x.com/AurelieRheumo/status/1932818904197255196/photo/1
• https://x.com/AurelieRheumo/status/1932818904197255196/photo/1

What happens in pre-RA when you stop #abatacept after 1 yr Rx At 6 yrs approx 60% on #Placebo V 50% who initially got #ABA Prolonged damped effect of development of #RA NNT for 1 yr is ~10 with a range as low as 6 #EULAR2025 @RheumNow @eular_org Abst#OP0004 https://t.co/1VOEaZ00Ia

• https://x.com/Janetbirdope/status/1932819742328312190/photo/1
• https://x.com/Janetbirdope/status/1932819742328312190/photo/1
• https://x.com/Janetbirdope/status/1932819742328312190/photo/1

#EULAR2025 Abstr#OP0075 Interesting that even among #SLE patients, no single definition of “Lupus Under Control” reached at least 50% agreement. Live Poll with clinicians in the room further highlighted the discordant. More works are needed - to help tailor management @RheumNow https://t.co/WzkQkMD23i

• https://x.com/Yuz6Yusof/status/1932820035346616662/photo/1

#EULAR2025 Abstr#OP0032 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 5 #SLE patients in Phase 1. Advantages over autologous/allogenic: -No apheresis -No conditioning chemo -Shorter hospital stays ~3days -Ability to redose in partial responder @RheumNow https://t.co/qimC94pVU1

• https://x.com/Yuz6Yusof/status/1932795893712933057/photo/1

Should we start strong in PsA? In the SPEED RCT (Coates et al), both early TNFi and combo csDMARDs outperformed step-up care in moderate-severe PsA. TNFi showed the most sustained benefit through 48w. Abstract#OP0089 @RheumNow #EULAR2025

First FcRn inhibitor in #IIM: In #ALKIVIA, SC efgartigimod PH20 improved TIS vs placebo at 24wks (50.45 vs 35.65, p=0.0004), with faster time to TIS≥20 (30 vs 71.5d) & TIS≥40 (113d vs NE). More major responders too (TIS>60: 34% vs 9.5%). @RheumNow #EULAR2025 #OP0002 https://t.co/75BfbXoVpL

• https://x.com/DrMiniDey/status/1932813824589234197/photo/1

Muscle biopsies form 3 treatment-naïve juvenile dermatomyositis (JDM) finds transcriptomic evidence of mitochondrial dysfunction consistently in JDM muscle, independent of interferon-driven inflammation. Treating mitochondrial dysfunction may improve JDM outcomes https://t.co/u5tMhT23si

How to patients with rheumatic diseases consume online health information? 78% used internet for health information 50% use it atleast a month 66% found online information superior 41% used social media! 80% using it to find treatment optio ns! @rheumnow #EULAR2025 https://t.co/diMCloFFVF

• https://x.com/bella_mehta/status/1932785862737330468/photo/1
• https://x.com/bella_mehta/status/1932785862737330468/photo/1
• https://x.com/bella_mehta/status/1932785862737330468/photo/1